BR102013030587B1 - Obtenção de extratos ou frações de inflorescências ou produtos de musa paradisiaca l., uso dos extratos ou frações de inflorescências ou produtos de musa paradisiaca l. e formulações com extratos e frações de inflorescências ou produtos de musa paradisiaca l - Google Patents
Obtenção de extratos ou frações de inflorescências ou produtos de musa paradisiaca l., uso dos extratos ou frações de inflorescências ou produtos de musa paradisiaca l. e formulações com extratos e frações de inflorescências ou produtos de musa paradisiaca l Download PDFInfo
- Publication number
- BR102013030587B1 BR102013030587B1 BR102013030587-1A BR102013030587A BR102013030587B1 BR 102013030587 B1 BR102013030587 B1 BR 102013030587B1 BR 102013030587 A BR102013030587 A BR 102013030587A BR 102013030587 B1 BR102013030587 B1 BR 102013030587B1
- Authority
- BR
- Brazil
- Prior art keywords
- fractions
- extracts
- products
- musa
- inflorescences
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 53
- 240000008790 Musa x paradisiaca Species 0.000 title claims abstract description 19
- 235000018290 Musa x paradisiaca Nutrition 0.000 title claims abstract description 15
- 239000000203 mixture Substances 0.000 title claims abstract description 13
- 241000234295 Musa Species 0.000 claims abstract description 22
- 229940079593 drug Drugs 0.000 claims abstract description 15
- 239000003814 drug Substances 0.000 claims abstract description 15
- 238000009472 formulation Methods 0.000 claims abstract description 11
- 208000024716 acute asthma Diseases 0.000 claims abstract description 10
- 230000001088 anti-asthma Effects 0.000 claims abstract description 10
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 10
- 208000023819 chronic asthma Diseases 0.000 claims abstract description 10
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 21
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 18
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 9
- 239000000399 hydroalcoholic extract Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- 235000003599 food sweetener Nutrition 0.000 claims description 6
- 239000003765 sweetening agent Substances 0.000 claims description 6
- 239000003463 adsorbent Substances 0.000 claims description 5
- 230000000845 anti-microbial effect Effects 0.000 claims description 5
- 239000003963 antioxidant agent Substances 0.000 claims description 5
- 230000003078 antioxidant effect Effects 0.000 claims description 5
- 235000006708 antioxidants Nutrition 0.000 claims description 5
- 239000003755 preservative agent Substances 0.000 claims description 5
- 230000002335 preservative effect Effects 0.000 claims description 5
- 239000002034 butanolic fraction Substances 0.000 claims description 4
- 238000002803 maceration Methods 0.000 claims description 4
- 238000003825 pressing Methods 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 235000010323 ascorbic acid Nutrition 0.000 claims description 3
- 229960005070 ascorbic acid Drugs 0.000 claims description 3
- 239000011668 ascorbic acid Substances 0.000 claims description 3
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims description 3
- 239000000686 essence Substances 0.000 claims description 3
- 230000002519 immonomodulatory effect Effects 0.000 claims description 3
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical group [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 3
- 239000004299 sodium benzoate Substances 0.000 claims description 3
- 235000010234 sodium benzoate Nutrition 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- 239000000758 substrate Substances 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 229940098465 tincture Drugs 0.000 claims description 3
- 230000001476 alcoholic effect Effects 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 238000010411 cooking Methods 0.000 claims description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 238000001802 infusion Methods 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 230000000284 resting effect Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000006673 asthma Diseases 0.000 abstract description 75
- 230000007423 decrease Effects 0.000 abstract description 42
- 241000699670 Mus sp. Species 0.000 abstract description 26
- 230000001154 acute effect Effects 0.000 abstract description 8
- 239000000924 antiasthmatic agent Substances 0.000 abstract description 8
- 230000004054 inflammatory process Effects 0.000 abstract description 4
- 230000009467 reduction Effects 0.000 abstract description 4
- 230000009885 systemic effect Effects 0.000 abstract description 4
- 206010061218 Inflammation Diseases 0.000 abstract description 3
- 239000002955 immunomodulating agent Substances 0.000 abstract description 3
- 229940121354 immunomodulator Drugs 0.000 abstract description 3
- 230000002584 immunomodulator Effects 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 238000002483 medication Methods 0.000 abstract description 3
- 230000004044 response Effects 0.000 abstract description 3
- 238000011161 development Methods 0.000 abstract description 2
- 238000002474 experimental method Methods 0.000 description 134
- 241001465754 Metazoa Species 0.000 description 76
- 210000004072 lung Anatomy 0.000 description 52
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 46
- 238000009117 preventive therapy Methods 0.000 description 44
- 238000009109 curative therapy Methods 0.000 description 43
- 238000002965 ELISA Methods 0.000 description 39
- 102000004127 Cytokines Human genes 0.000 description 38
- 108090000695 Cytokines Proteins 0.000 description 38
- 239000000243 solution Substances 0.000 description 26
- 238000010186 staining Methods 0.000 description 24
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 23
- 210000004969 inflammatory cell Anatomy 0.000 description 23
- 230000002685 pulmonary effect Effects 0.000 description 21
- 229960003957 dexamethasone Drugs 0.000 description 19
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 19
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 16
- 102100040247 Tumor necrosis factor Human genes 0.000 description 16
- 239000000463 material Substances 0.000 description 16
- 230000002757 inflammatory effect Effects 0.000 description 15
- 238000011282 treatment Methods 0.000 description 15
- 230000006872 improvement Effects 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 210000002966 serum Anatomy 0.000 description 12
- 230000003247 decreasing effect Effects 0.000 description 10
- 102000015696 Interleukins Human genes 0.000 description 9
- 108010063738 Interleukins Proteins 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- 229940047122 interleukins Drugs 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- 239000006286 aqueous extract Substances 0.000 description 6
- 238000005192 partition Methods 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 230000004968 inflammatory condition Effects 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 239000002036 chloroform fraction Substances 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000007489 histopathology method Methods 0.000 description 4
- 230000003449 preventive effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 230000005180 public health Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- 238000008157 ELISA kit Methods 0.000 description 2
- 241001371195 Lafoensia pacari Species 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 201000009961 allergic asthma Diseases 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000012754 cardiac puncture Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 238000005202 decontamination Methods 0.000 description 2
- 230000003588 decontaminative effect Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 239000002044 hexane fraction Substances 0.000 description 2
- 230000001632 homeopathic effect Effects 0.000 description 2
- 239000002045 hydroalcoholic fraction Substances 0.000 description 2
- 230000008105 immune reaction Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000005418 vegetable material Substances 0.000 description 2
- 230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- PFWLFWPASULGAN-UHFFFAOYSA-N 7-methylxanthine Chemical compound N1C(=O)NC(=O)C2=C1N=CN2C PFWLFWPASULGAN-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010064823 Asthmatic crisis Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241001180744 Curitiba Species 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 1
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 1
- 229920002079 Ellagic acid Polymers 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 208000005279 Status Asthmaticus Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000001022 anti-muscarinic effect Effects 0.000 description 1
- 208000010216 atopic IgE responsiveness Diseases 0.000 description 1
- 108010030694 avidin-horseradish peroxidase complex Proteins 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229940084953 dexamethasone 0.5 mg Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229960002852 ellagic acid Drugs 0.000 description 1
- 235000004132 ellagic acid Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000401 methanolic extract Substances 0.000 description 1
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (16)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR102013030587-1A BR102013030587B1 (pt) | 2013-11-28 | 2013-11-28 | Obtenção de extratos ou frações de inflorescências ou produtos de musa paradisiaca l., uso dos extratos ou frações de inflorescências ou produtos de musa paradisiaca l. e formulações com extratos e frações de inflorescências ou produtos de musa paradisiaca l |
PCT/BR2014/000026 WO2014117238A1 (pt) | 2013-02-01 | 2014-01-30 | Extratos e frações de musa paradisiaca l. e seus usos |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR102013030587-1A BR102013030587B1 (pt) | 2013-11-28 | 2013-11-28 | Obtenção de extratos ou frações de inflorescências ou produtos de musa paradisiaca l., uso dos extratos ou frações de inflorescências ou produtos de musa paradisiaca l. e formulações com extratos e frações de inflorescências ou produtos de musa paradisiaca l |
Publications (2)
Publication Number | Publication Date |
---|---|
BR102013030587A2 BR102013030587A2 (pt) | 2015-03-24 |
BR102013030587B1 true BR102013030587B1 (pt) | 2021-01-05 |
Family
ID=52780241
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR102013030587-1A BR102013030587B1 (pt) | 2013-02-01 | 2013-11-28 | Obtenção de extratos ou frações de inflorescências ou produtos de musa paradisiaca l., uso dos extratos ou frações de inflorescências ou produtos de musa paradisiaca l. e formulações com extratos e frações de inflorescências ou produtos de musa paradisiaca l |
Country Status (1)
Country | Link |
---|---|
BR (1) | BR102013030587B1 (pt) |
-
2013
- 2013-11-28 BR BR102013030587-1A patent/BR102013030587B1/pt active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
BR102013030587A2 (pt) | 2015-03-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ulbricht et al. | An evidence-based systematic review of elderberry and elderflower (Sambucus nigra) by the Natural Standard Research Collaboration | |
Grundmann | Aloe vera gel research review | |
Naseri et al. | Effect of topical marshmallow (Althaea officinalis) on atopic dermatitis in children: A pilot double‐blind active‐controlled clinical trial of an in‐silico‐analyzed phytomedicine | |
Djerroua et al. | Evaluation of Pistacia lentiscus fatty oil effects on glycemic index, liver functions and kidney functions of New Zealand rabbits | |
US20160331794A1 (en) | Composition for use in the treatment of persistent cough | |
Uttra | Assessment of antiarthritic potential of Ephedra gerardiana by in vitro and in vivo methods | |
Abreu et al. | Lectin isolated from the red marine alga Solieria filiformis (Kützing) PW Gabrielson: Secondary structure and antidepressant-like effect in mice submitted to the lipopolysaccharide-induced inflammatory model of depression | |
Vieira et al. | On the bioactivity of Echinacea purpurea extracts to modulate the production of inflammatory mediators | |
Mehraban et al. | Efficacy and safety of add-on Viola odorata L. in the treatment of COVID-19: A randomized double-blind controlled trial | |
Landor et al. | Efficacy and acceptance of a commercial Hoodia parviflora product for support of appetite and weight control in a consumer trial | |
Odo et al. | Acute toxicity investigation and anti-diarrhoeal effect of the chloroform–methanol extract of the seeds of Persea americana in albino rats | |
Vitali et al. | Inhibition of intestinal motility and secretion by extracts of Epilobium spp. in mice | |
WO2014117238A1 (pt) | Extratos e frações de musa paradisiaca l. e seus usos | |
Sarker et al. | In-vitro and in-vivo pharmacological activities with phytochemical evaluation of methanolic extract of Microcos paniculata stem barks | |
Reis et al. | The effects of supplementing Hancornia speciosa (Mangaba) on bowel motility and inflammatory profile of wistar rats | |
Wang et al. | Gleditsiae sinensis fructus Pills combined with Jujubae fructus attenuate chronic bronchitis via regulation of AGE-RAGE signaling pathway | |
Ghazanfari et al. | Inflammatory bio-marker changes in hemodialysis patients with pruritus receiving violet oil: A randomized controlled trial | |
BR102013030587B1 (pt) | Obtenção de extratos ou frações de inflorescências ou produtos de musa paradisiaca l., uso dos extratos ou frações de inflorescências ou produtos de musa paradisiaca l. e formulações com extratos e frações de inflorescências ou produtos de musa paradisiaca l | |
Yihang et al. | Acute toxicity study of Aspidopterys obcordata aqueous extract in Sprague-Dawley rats | |
Watts et al. | Slippery elm, its biochemistry, and use as a complementary and alternative treatment for laryngeal irritation | |
Stengler | The Natural Physician's Healing Therapies: Proven Remedies Medical Doctors Don't Know | |
JP3257977B2 (ja) | 緑豆抽出エキス | |
Dasgupta et al. | Activated charcoal is more effective than equilibrium dialysis in removing Chinese medicines Chan Su and Dan Shen from serum and activated charcoal also prevents further absorption of these agents from GI tract in mice: monitoring the effect in clinical laboratory by measuring digoxin activity in serum | |
Froldi | The Use of Medicinal Plants in Blood Vessel Diseases: The Influence of Gender | |
Liao et al. | Hylocereus undatus flower suppresses DSS-induced colitis in mice by reducing intestinal inflammation, repairing the intestinal physical barrier, and modulating gut and lung microbiota |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B03A | Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/11/2013, OBSERVADAS AS CONDICOES LEGAIS. |
|
B22L | Other matters related to patents and certificates of addition of invention: notification of licence offer (art 64 par 1 of lpi) |
Free format text: CONDICOES CONTRATUAIS: 1) ROYALTIES: 5% (CINCO POR CENTO) DO PRECO DE VENDA, LIVRE DE IMPOSTOS; 2) PRAZO: ATE O TERMINO DE VIGENCIA DA PATENTE EM 28.11.2033; 3) CONDICOES DE PAGAMENTO: ANUAL, EM FUNCAO DAS VENDAS APURADAS NO PERIODO; 4) DISPONIBILIDADE DE ?KNOW-HOW?: SIM; 5) ASSISTENCIA TECNICA: NAO. - OBS: CONSULTA A CARTA PATENTE PODERA SER FEITA ATRAVES DO ENDERECO ELETRONICO WWW.INPI.GOV.BR = NO ACESSO RAPIDO = BUSCA WEB = PATENTE. PARA ACESSAR, CADASTRE-SE NO PORTAL DO INPI E USE LOGIN E SENHA |
|
B22L | Other matters related to patents and certificates of addition of invention: notification of licence offer (art 64 par 1 of lpi) |
Free format text: CONDICOES CONTRATUAIS: 1) ROYALTIES: 5% (CINCO POR CENTO) DO PRECO DE VENDA, LIVRE DE IMPOSTOS; 2) PRAZO: ATE O TERMINO DE VIGENCIA DA PATENTE EM 28.11.2033; 3) CONDICOES DE PAGAMENTO: ANUAL, EM FUNCAO DAS VENDAS APURADAS NO PERIODO; 4) DISPONIBILIDADE DE ?KNOW-HOW?: SIM; 5) ASSISTENCIA TECNICA: NAO. - OBS: CONSULTA A CARTA PATENTE PODERA SER FEITA ATRAVES DO ENDERECO ELETRONICO WWW.INPI.GOV.BR = NO ACESSO RAPIDO = BUSCA WEB = PATENTE. PARA ACESSAR, CADASTRE-SE NO PORTAL DO INPI E USE LOGIN E SENHA. |
|
B22L | Other matters related to patents and certificates of addition of invention: notification of licence offer (art 64 par 1 of lpi) |
Free format text: CONDICOES CONTRATUAIS: 1) ROYALTIES: 5% (CINCO POR CENTO) DO PRECO DE VENDA, LIVRE DE IMPOSTOS; 2) PRAZO: ATE O TERMINO DE VIGENCIA DA PATENTE EM 28.11.2033; 3) CONDICOES DE PAGAMENTO: ANUAL, EM FUNCAO DAS VENDAS APURADAS NO PERIODO; 4) DISPONIBILIDADE DE ?KNOW-HOW?: SIM; 5) ASSISTENCIA TECNICA: NAO. - OBS: CONSULTA A CARTA PATENTE PODERA SER FEITA ATRAVES DO ENDERECO ELETRONICO WWW.INPI.GOV.BR = NO ACESSO RAPIDO = BUSCA WEB = PATENTE. PARA ACESSAR, CADASTRE-SE NO PORTAL DO INPI E USE LOGIN E SENHA. |
|
B22L | Other matters related to patents and certificates of addition of invention: notification of licence offer (art 64 par 1 of lpi) |
Free format text: CONDICOES CONTRATUAIS: 1) ROYALTIES: 5% (CINCO POR CENTO) DO PRECO DE VENDA, LIVRE DE IMPOSTOS; 2) PRAZO: ATE O TERMINO DE VIGENCIA DA PATENTE EM 28.11.2033; 3) CONDICOES DE PAGAMENTO: ANUAL, EM FUNCAO DAS VENDAS APURADAS NO PERIODO; 4) DISPONIBILIDADE DE ?KNOW-HOW?: SIM; 5) ASSISTENCIA TECNICA: NAO. - OBS: CONSULTA A CARTA PATENTE PODERA SER FEITA ATRAVES DO ENDERECO ELETRONICO WWW.INPI.GOV.BR = NO ACESSO RAPIDO = BUSCA WEB = PATENTE. PARA ACESSAR, CADASTRE-SE NO PORTAL DO INPI E USE LOGIN E SENHA. |
|
B22L | Other matters related to patents and certificates of addition of invention: notification of licence offer (art 64 par 1 of lpi) |
Free format text: CONDICOES CONTRATUAIS: 1) ROYALTIES: 5% (CINCO POR CENTO) DO PRECO DE VENDA, LIVRE DE IMPOSTOS; 2) PRAZO: ATE O TERMINO DE VIGENCIA DA PATENTE EM 28.11.2033; 3) CONDICOES DE PAGAMENTO: ANUAL, EM FUNCAO DAS VENDAS APURADAS NO PERIODO; 4) DISPONIBILIDADE DE ?KNOW-HOW?: SIM; 5) ASSISTENCIA TECNICA: NAO. - OBS: CONSULTA A CARTA PATENTE PODERA SER FEITA ATRAVES DO ENDERECO ELETRONICO WWW.INPI.GOV.BR - NO ACESSO RAPIDO = BUSCA DE PROCESSOS = FACA LOGIN COM SENHA OU TECLE CONTINUAR = PATENTE = DIGITE O NUMERO DO PROCESSO = PESQUISAR. PARA ACESSAR, CADASTRE-SE NO PORTAL DO INPI. |
|
B22L | Other matters related to patents and certificates of addition of invention: notification of licence offer (art 64 par 1 of lpi) |
Free format text: CONDICOES CONTRATUAIS: 1) ROYALTIES: 5% (CINCO POR CENTO) DO PRECO DE VENDA, LIVRE DE IMPOSTOS; 2) PRAZO: ATE O TERMINO DE VIGENCIA DA PATENTE EM 28.11.2033; 3) CONDICOES DE PAGAMENTO: ANUAL, EM FUNCAO DAS VENDAS APURADAS NO PERIODO; 4) DISPONIBILIDADE DE ?KNOW-HOW?: SIM; 5) ASSISTENCIA TECNICA: NAO. - OBS: CONSULTA A CARTA PATENTE PODERA SER FEITA ATRAVES DO ENDERECO ELETRONICO WWW.INPI.GOV.BR - NO ACESSO RAPIDO = BUSCA DE PROCESSOS = FACA LOGIN COM SENHA OU TECLE CONTINUAR = PATENTE = DIGITE O NUMERO DO PROCESSO = PESQUISAR. PARA ACESSAR, CADASTRE-SE NO PORTAL DO INPI. |
|
B22L | Other matters related to patents and certificates of addition of invention: notification of licence offer (art 64 par 1 of lpi) |
Free format text: CONDICOES CONTRATUAIS: 1) ROYALTIES: 5% (CINCO POR CENTO) DO PRECO DE VENDA, LIVRE DE IMPOSTOS; 2) PRAZO: ATE O TERMINO DE VIGENCIA DA PATENTE EM 28.11.2033; 3) CONDICOES DE PAGAMENTO: ANUAL, EM FUNCAO DAS VENDAS APURADAS NO PERIODO; 4) DISPONIBILIDADE DE ?KNOW-HOW?: SIM; 5) ASSISTENCIA TECNICA: NAO. - OBS: CONSULTA A CARTA PATENTE PODERA SER FEITA ATRAVES DO ENDERECO ELETRONICO WWW.INPI.GOV.BR - NO ACESSO RAPIDO = BUSCA DE PROCESSOS = FACA LOGIN COM SENHA OU TECLE CONTINUAR = PATENTE = DIGITE O NUMERO DO PROCESSO = PESQUISAR. PARA ACESSAR, CADASTRE-SE NO PORTAL DO INPI. |